Collectively, these data show on a laboratory and clinical level that individuals with FCGR2A-p.166His and FCGR3A-p.176Val have enhanced responses to antibody-mediated cancer immunotherapy and genotyping may be useful to stratify treatment regimens and potentially adjust dosing to prevent side effects. This evidence concerns the gene FCGR3A and cancer.